Ekso Bionics (NASDAQ:EKSO) posted its quarterly earnings results on Thursday. The company reported ($1.88) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.56) by ($1.32), MarketWatch Earnings reports. Ekso Bionics had a negative return on equity of 206.13% and a negative net margin of 156.16%. The firm had revenue of $2.26 million during the quarter, compared to analyst estimates of $1.85 million.
Shares of EKSO traded down $0.84 during mid-day trading on Friday, reaching $6.52. 634,040 shares of the company’s stock traded hands, compared to its average volume of 515,526. The business’s 50-day moving average price is $6.52 and its 200-day moving average price is $3.08. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.53 and a current ratio of 1.86. Ekso Bionics has a 12 month low of $2.25 and a 12 month high of $18.15.
A number of equities analysts have issued reports on the stock. Zacks Investment Research cut shares of Ekso Bionics from a “buy” rating to a “hold” rating in a report on Thursday, June 18th. Aegis cut their target price on shares of Ekso Bionics from $15.00 to $13.00 and set a “buy” rating on the stock in a report on Thursday, May 21st. Finally, HC Wainwright reissued a “buy” rating and issued a $12.00 target price on shares of Ekso Bionics in a report on Friday. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. The company has an average rating of “Buy” and an average target price of $9.25.
Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, and military markets in North America, Europe, the Middle East, and Africa. The company operates through EksoHealth and EksoWorks segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries and hemiplegia due to stroke.
Featured Story: How Buying a Call Option Works
Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with MarketBeat.com's FREE daily email newsletter.